Comparative Pharmacology
Head-to-head clinical analysis: SPRX 105 versus TRYNGOLZA AUTOINJECTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SPRX 105 versus TRYNGOLZA AUTOINJECTOR.
SPRX-105 vs TRYNGOLZA (AUTOINJECTOR)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SPRX-105 is a dual dopamine D2 and serotonin 5-HT1A receptor partial agonist, functioning as a postsynaptic antagonist and presynaptic agonist at D2 receptors, and as a partial agonist at 5-HT1A receptors, modulating neurotransmitter release.
Selective inhibitor of protein kinase C theta (PKCθ), reducing T cell activation and cytokine production.
SPRX-105 is administered orally at a dose of 50 mg once daily.
0.5 mg subcutaneously once daily.
None Documented
None Documented
12-15 hours in healthy adults; extended to 24-30 hours in renal impairment.
Terminal elimination half-life is approximately 21 days (range 14–28 days), consistent with slow clearance from plasma due to target-mediated drug disposition.
Primarily renal (70-80% unchanged) with 15-20% biliary/fecal elimination.
Primarily eliminated via the reticuloendothelial system; no significant renal or biliary excretion. <1% excreted unchanged in urine.
Category C
Category C
Unknown
Unknown